This update serves to clarify the fact that GE has licensed its production reagents exclusively to CytoGenix for the company to use in compound manufacturing.
NEW YORK, March 23 (GenomeWeb News) - GE Healthcare will exclusively provide its DNA production reagents to CytoGenix where the intended application is the manufacture of therapeutic compounds, CytoGenix said today in a statement.
A CytoGenix spokesperson said other labs or companies can license the reagents for purposes other than compound manufacturing.
The companies did not disclose financial terms of the agreement.
Houston, Tex.-based CytoGenix manufactures DNA-based vaccines and therapeutics for infectious diseases, inflammatory disorders, and cancer.